Prostate cancer (PC) remains a major public health issue, and debate over screening for PC with prostate-specific antigen (PSA) continues despite evidence for benefits of screening. The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a 21% reduction in PC mortality (0.41% vs 0.52%) in the screening arm relative to the control arm in an intention-to-screen analysis with a median follow-up of 11 years (1). However, the ERSPC trial is, so far, the only randomized trial that has shown a statistically significant reduction in PC-specific mortality (2, 3) .
The main purpose of PC screening is to decrease deaths from the disease, although screening may also have other beneficial effects. However, it may be argued that reduced cancer-specific mortality is not a sufficient piece of evidence for the effectiveness of screening if all-cause mortality is not reduced as well (4) . This is especially important because all-cause mortality is less vulnerable to attribution bias in regard to cause of death. All-cause mortality has not been reduced by PC screening in any of the studies published so far (1, 2, 3, 5) .
Moreover, screening for PC always has negative consequences, such as overdiagnosis and overtreatment. Therefore, screening cannot be readily recommended as a public health policy while the balance of benefits and harms remains uncertain (6) .
We present here the mortality results from the Finnish trial, the largest component of the ERSPC trial. We also analyzed the differences in PC incidence and treatment modalities between the trial arms.
Methods
The Finnish Prostate Cancer Screening Trial was the largest component of the randomized, multicenter ERSPC trial. The Finnish trial included 80 144 men born between 1929 and 1944 (aged 55, 59, 63, or 67 years at entry) identified from the Finnish Population Registry. After exclusion of men with a previous PC diagnosis, a random sample of men in each age group was allocated to the screening arm (SA) annually in the period from 1996 to 1999. The remaining men formed the control arm (CA) and were not contacted.
This randomization led to an equal age distribution in the trial arms and to a ratio of approximately 1:1.5 (SA:CA). The randomization was made at the Population Registry using computer-generated pseudorandom numbers. Written, informed consent was given by the participating men in the SA. The study protocol was approved by the ethical committees of Helsinki University Hospital and Tampere University Hospital. Permission to use cancer registry data was obtained from the Research and Development Centre for Welfare and Health (STAKES, currently part of the National Institute of Health and Welfare).
Men in the SA were invited to a local cancer society outpatient clinic for the screening test (ie, determination of serum PSA concentration). Men with a PSA greater than or equal to 4.0 ng/mL were referred to a local urological clinic for diagnostic examinations, including digital rectal examination, transrectal ultrasound, and prostate biopsy. Initially sextant biopsies were used, but 10 to 12 biopsy cores were adopted in 2002 (ie, during the second round). Men with PSA levels of 3.0 to 3.99 ng/mL were referred to an additional test, which in the period from 1996 to 1998 was digital rectal examination and since 1999 was determination of the free/total PSA ratio with a cut-off point of 16%. Men with a suspicious digital rectal examination or free/total PSA ratio less than or equal to 16% were referred for diagnostic examinations in the same manner as those with PSA greater than or equal to 4.0 ng/mL.
Men in the SA were reinvited to the second and third screening rounds 4 and 8 years after the first screen. Men aged older than 71 years were no longer invited, and thus men aged 67 years at the initial screen were invited only twice. Information on vital status and place of residence was obtained from the Population Registry. Men with PC and those who had emigrated from the study area were not reinvited.
An interval cancer was defined as a cancer detected less than 4 years after the PSA test in a screen-negative man. Cancers in nonparticipants were not regarded as interval cancers, nor were those diagnosed more than 4 years after the previous screen.
PCs were categorized as low, moderate, and high risk and separately as advanced. A low-risk PC was defined as a cancer with T1 to T2 and Gleason score less than or equal to 6. Moderate risk PC was defined as T1 to T2 and Gleason score 7 or T3 with a Gleason score less than or equal to 7. High risk PCs were either T1 to T3 and Gleason score 8 to 10 or T4 or M1 or N1 (with any Gleason score). Advanced PC was defined as a PC with one or more of the following characteristics: T3 to T4, M1, or N1.
Primary treatment data were retrieved from hospital records and included radical prostatectomy, radiation therapy (external beam radiation or brachytherapy), endocrine therapy (luteinizing hormone releasing hormone agonist, antiandrogen, or both or surgical castration), or observation (either watchful waiting or active surveillance).
The follow-up started at the first of January in the year of randomization (1996) (1997) (1998) (1999) ) and ended at death, emigration from Finland, or the common closing date for both incidence and mortality analyses (December 31, 2010). Follow-up time was truncated at 12 years. Information on cancers detected outside the screening protocol (interval cancers and those in nonparticipants and the control arm) were obtained from the nationwide, populationbased Finnish Cancer Registry, which has 99% coverage of all solid cancers diagnosed in Finland (7) . All randomized men were analyzed regardless of their participation (in accordance with the intention-to-screen principle). Because of logistic difficulties, 1671 men were not invited despite having been randomized to the SA. These men were included in the SA (as nonparticipants).
In Finland, all deaths are registered in the causes of death registry by Statistics Finland (http://www.stat.fi), and the 10th revision of the International Classification of Diseases (ICD-10) has been used since 1996. To validate the causes of death in our study, all deaths occurring in the period from 1996 to 2003 among men diagnosed with PC (regardless of randomization arm) were reviewed by a cause-of-death committee. An excellent agreement (97.7%; κ = 0.95) was shown between the official causes-of-death registry and the cause-of-death committee (8) . In our study, men who had PC (code C61 in ICD-10) as the underlying cause of death in the official causes of death registry were defined as PC deaths (main outcome).
The ERSPC trial was registered (http://registered-trials.com, number ISRCTN49127736). Because the Finnish trial was not planned as a stand-alone trial, no separate power calculations were performed. The number that needed to be invited to screening was calculated as the inverse of the absolute reduction of risk of PC death between the trial arms. The number of PCs that needed to be detected to avoid a PC death was calculated as the aforementioned inverse absolute risk multiplied by the excess of the PC incidence of between the trial arms. Cumulative hazard for risk of PC diagnosis and PC death were estimated with the Nelson-Aalen method (9,10). Hazard ratios (HRs) were estimated for PC and all-cause mortality for the screening arm relative to the control arm using Cox proportional hazard model. Proportional hazard assumption was verified with Schoenfeld residuals.
Statistical Analysis
The treatment modalities between the trial arms were compared using the Pearson χ 2 test (eg, radical prostatectomy vs other treatment modality). All statistical analyses were performed using Stata 8.2 (StataCorp, College Station, TX). A P value of less than .05 was considered statistically significant. All statistical tests were two-sided.
results
There were 31 866 men in the SA and 48 278 men in the CA ( Figure 1 ). Owing to randomized design, the age distribution in both arms was similar (median age = 58.7 years at entry in both arms). Age group proportions at entry in the SA and CA, respectively, were 32.9 % vs 33.0 % for 55 years, 26.2 % vs 26.3 % for 59 years, 21.6 % vs 21.5 % for 63 years, and 19.2 % vs 19.2 % for 67 years.
The mean follow-up time was 10.8 years in both arms (standard deviation = 2.8 years in both arms), and the median was 12.0 years. Of men in the SA, 74.6% (n = 23 771) attended screening at least once. In the SA, 2883 PCs were diagnosed (cumulative incidence = 9.0%; 8.8 per 1000 person-years), and 3337 PCs were diagnosed in the CA (6.9%; 6.6 per 1000 person-years). PC incidence was thus substantially higher in the SA (HR = 1.34, 95% confidence interval [CI] = 1.27 to 1.40; P < .001) (Figure 2 ). PC JNCI | Articles 721 jnci.oxfordjournals.org incidence was similar in the nonattending men in the SA (6.3 per 1000 person-years) and CA (HR = 0.97, 95% CI = 0.88 to 1.06). There were altogether 222 interval cancers in the SA (cumulative incidence = 0.70%; of these, 14.4% were of high risk).
The incidence of advanced PC was 1.2 per 1000 person-years in the SA and 1.6 per 1000 person-years in the CA (HR = 0.73, 95% CI = 0.64 to 0.82; P < .001). The incidence of low-and moderaterisk PCs was higher in the SA than in the CA (Table 1) . Incidence for low-risk PC was 5.4 per 1000 person-years in the SA and 3.1 per 1000 person-years in the CA (HR = 1.75, 95% CI = 1.64 to 1.87; P < .001); Incidence for moderate-risk PC was 2.2 per 1000 person-years in the SA and 2.1 per 1000 person-years in the CA (HR = 1.03, 95% CI = 0.94 to 1.14; P = .48); and incidence for highrisk PC was 1.2 per 1000 person-years in the SA and 1.4 per 1000 person-years in the CA (HR = 0.86, 95% CI = 0.76 to 0.97; P = .02).
Altogether 6618 men died in the SA during follow-up (cumulative mortality = 20.8%), and of them, 149 died of PC (cumulative mortality = 0.47%) ( Table 2 ). In the CA, there were 10 079 deaths (20.9%), of which 266 (0.55%) were caused by PC (ie, screening prevented 27 PC deaths). The hazard ratio between trial arms was 0.85 (95% CI = 0.69 to 1.04; P = .10) for PC death. A difference in PC mortality emerged after approximately 8 years of followup ( Figure 3) . The hazard ratio corresponds with the number that needed to be invited to screening to avoid one PC death of 1199 (95% CI = 546 to 6075). The number of PCs that needed to be detected in order to avert a PC death was 25 (95% CI = 11 to 126). The hazard ratio for overall death between trial arms was 0.99 (95% CI = 0.96 to 1.02; P = .69). No statistically significant difference was observed in any other cause-of-death groups between trial arms ( Table 2) . Statistically significant differences were observed in the treatment modalities between the trial arms, with men in the SA being more likely to be treated with radical prostatectomy for moderateto high-risk PCs than men in the CA (Table 3) .
In the SA, the cumulative PC mortality was lower in the men who attended screening at least once (0.38%; HR compared with CA = 0.66, 95% CI = 0.52 to 0.84; P < .001) than in the men who never attended screening (0.72%). The relative hazard ratio of these nonattending men compared with CA was 1.54 (95% CI = 1.16 to 2.05; P < .001), and the HR compared with the attending men in the SA was 2.34 (95% CI = 1.68 to 3.25; P < .001).
Discussion
In the Finnish Prostate Cancer Screening Trial, the overall PC incidence at 12 years of follow-up was higher in the SA than in the CA because of overdiagnosis, but the incidence of both high-risk PC and advanced PC was statistically significantly lower in the SA. The cumulative PC mortality was 0.47% in the screening arm and 0.55% in the control arm, yielding a hazard ratio of 0.85 (95% CI = 0.69 to 1.04), with a number that needed to be invited to screening of 1199 and a number of PCs that needed to be detected of 25. The number that needed to be invited to screening and the number of cancers that needed to be detected to avoid one PC death were comparable with respective numbers estimated in the joint ERSPC analysis, which showed a statistically significant 21% reduction in PC-specific mortality. We observed no difference in all-cause mortality between trial arms (HR = 0.99, 95% CI = 0.96 to 1.02).
The ERSPC trial was a multicenter trial in seven European countries. Besides a common core protocol, there were differences between centers regarding factors such as screening interval, biopsy threshold, targeted age range, and mode of recruitment (1) . Therefore, it is understandable that there were differences in screening results between the centers. The observed difference in mortality effect between centers was caused by interplay between varying baseline risks of PC between study populations and the numerous differences in screening protocols. For example, in the Swedish center, the relative mortality reduction effect was substantial, 0.44% in the SA vs 0.78% in the CA (5), but the difference between the Finnish and Swedish results is mainly in the mortality in the control arms (0.55% vs 0.78%), indicating different baseline risks between populations or longer follow-up after diagnosis (in our trial, median follow-up was 5.0 years in the SA and 3.8 years in the CA). The Swedish trial had longer follow-up (calculated both from randomization and from diagnosis). In both trials, the difference in mortality became evident only after approximately 8 years. These follow-up times are still short in the light of the treatment studies that have shown that the long-term mortality of PC can be seen only after at least 20 years from the diagnosis (11) . Also, the Swedish component had a slightly younger age range than the other centers in the ERSPC, but this alone is unlikely to explain the differences because the age differences were not substantial between the centers and the differentials in mortality effect by age were not large or systematic (1) . One must also bear in mind that the statistical power in a single ERSPC center was insufficient for conclusive evidence on screening, which is why the trial was based on international collaboration (12) . Nevertheless, the Finnish trial was the largest component of the ERSPC trial, with more than 80 000 men and 415 PC deaths, which is more than in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (76 693 and 174, respectively) (3) or the Swedish component of the ERSPC trial (19 904 and 122, respectively) (5).
In our trial, a small, non-statistically significant reduction in PC mortality in the SA was found, but no effect was found in all-cause mortality. There were no major differences in other disease-specific causes of death.
Differential treatment modalities may have affected PC mortality because the men in the SA were more likely to be treated with radical prostatectomy for moderate-to high-risk PCs when stratified by risk group. It is difficult to assess how this could affect the mortality results because the relative effectiveness of various treatment options has not been well established and overdiagnosis complicates the interpretation of treatment frequencies. A similar dissimilarity in treatment modalities was observed previously in a combined analysis from the eight centers of the ERSPC trial: radical prostatectomy and active surveillance were more often chosen in the SA and endocrine therapy in the CA (13) . This may reflect a screening effect: the inherent differences between the clinically emerged PC and screen-detected PC rather than actual bias in the treatment between trial arms. Had there been bias in the SA toward more curatively aimed treatment, this bias would be likely to magnify rather than dilute the difference in relative PC mortality.
As in other screening studies, overdiagnosis in the SA was substantial (roughly 30% if estimated on the basis of the excess of cases in the SA if the cumulative risk of PC had been the same as in the CA). In the joint ERSPC analysis, the corresponding proportion was roughly 60% (1), as it was in the Swedish trial (5). In the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, with substantial contamination in the CA, the proportion of excess PC diagnoses was 16% (3) . Compared with these other trials, the degree of overdiagnosis was moderate in the Finnish trial, even though these estimates of overdiagnosis are crude and do not take into account the lead time (earlier diagnosis in the SA).
So far, we have no estimate of the contamination in the CA of the Finnish trial. Therefore it remains unknown whether contamination affected the relatively small effect on relative PC mortality. In a questionnaire survey among Finnish physicians, 18% of the responders reported having systematically screened asymptomatic men with PSA in 1999 and 9% of the responders reported such in 2007. In addition, 70% used PSA screening occasionally (14) . No systematic large-scale comparison of contamination between the major centers of ERSPC has been published, but in the latest mortality analysis, no major differences in the proportion of T1c cancer in the CAs between centers were seen (40%-46% for the Dutch, Swedish, and Finnish centers) (1).
Population-based trials often have difficulties covering the entire target population because some invited subjects always choose not to participate. In the Finnish trial, the proportion participating was acceptable (69%-71% at each round) (15) . The nonparticipant men differ in several respects from the participants, constituting confounding known as the "healthy screenee bias" (16) . The reasons for not participating may be various, such as not finding a suitable time to attend the screening test, not being fit enough to participate, or having already been tested for the target disease. An analysis from the Finnish Prostate Cancer Screening Trial revealed that the most commonly given reasons for nonparticipation were forgetting the invitation (51%), previous PSA testing (41%), not wanting to think of PC (39%), and regarding possible further examinations as unpleasant (28%) (17) . As expected, the nonparticipant men in our trial had higher PC mortality than those in the CA. Therefore, these nonattending men present a high-risk group. We included the nonparticipant men in the SA according to the intention-to-screen principle, which reduced the difference in mortality between the SA and CA.
The cumulative incidence of interval cancers was comparable with that of the Swedish and Dutch centers of ERSPC (18) . It is possible that more frequent screening could be more effective in reducing the incidence of advanced PC and thus mortality, as a recent report comparing Dutch and Swedish trials suggests (19) . This notion is also supported by a simulation study that concluded that the screening interval has a more substantial effect on mortality reduction than the age at the onset of screening (20) . In this simulation, shortening the screening interval to 2 years was estimated to improve the mortality reduction by 7.6 percentage points (95% CI = 6.5 to 8.9). However, biennial screening adds costs to screening and is likely to also produce more adverse effects, such as overdiagnosis.
This study has several strengths, such as the randomized design and a large study population. The population-based design renders the results directly applicable to the general population. In Finland, the Finnish Cancer Registry is very comprehensive (7), data from the Population Registry and Causes of Death Registry are readily available for researchers, and information can be linked based on the unique personal identity number assigned to each citizen. Also, the death certificate data are very accurate, which is a cornerstone of any cause-specific mortality study (8) . Furthermore, the randomization was successful, as both the age distribution and overall mortality were equal between the trial arms.
Contamination in the CA dilutes the observed difference in PC mortality between trial arms. A shortcoming in our trial is that we have no measure of the degree of contamination in the CA. Furthermore, if there was a bias in treatment modalities between the SA and CA, it would magnify rather than dilute the screening effect.
With a relatively conservative screening protocol at 12 years of follow-up, screening resulted in a small, yet non-statistically significant, mortality reduction. The degree of overdiagnosis was lower than in previous studies with a more prominent mortality effect. It remains to be seen whether the difference between trial arms increases with further follow-up. A more aggressive screening protocol is likely to produce a more substantial reduction in PC mortality, but this beneficial effect should be reviewed in the light of adverse effects of screening, such as overdiagnosis. 
